Novo Nordisk, Inc. v. Wells Pharmacy Network, LLC

District Court, M.D. Florida·Decided April 4, 2025·No. 5:23-cv-00689·Unknown

Opinion

UNITED STATES DISTRICT COURT MIDDLE DISTRICT OF FLORIDA OCALA DIVISION

NOVO NORDISK, INC.,

Plaintiff,

v. Case No: 5:23-cv-689-ACC-PRL

WELLS PHARMACY NETWORK, LLC,

Defendant.

ORDER This cause, upon referral, comes before the Court on a Motion for Entitlement to Costs and Attorney’s Fees filed by Defendant Wells Pharmacy Network, LLC (“Defendant”). (Doc. 52). Defendant moves for entitlement to costs and attorney’s fees pursuant to Local Rule 7.01(a), seeking an award of $250,289.00 in attorney’s fees and $1,807.80 in costs as the purported prevailing party under Florida’s Deceptive and Unfair Trade Practices Act (“FDUTPA”) and the Lanham Act. (Doc. 52 at p. 2; Doc. 52-1). Plaintiff Novo Nordisk, Inc. (“Plaintiff”) opposes Defendant’s motion, asserting that an award of attorney’s fees and costs under FDUTPA and the Lanham Act is premature at this stage, given its recent appeal filed on March 11, 2025 (Doc. 53), which may obviate the need to pay any fees or costs. (Doc. 55). Given the pending appeal, Defendant’s motion is due to be denied without prejudice as premature because FDUTPA precludes an award of attorney’s fees until after the exhaustion of all appeals. I. BACKGROUND On November 29, 2023, Plaintiff filed suit against Defendant, alleging, inter alia, violations of FDUTPA, Fla. Stat. § 501.201 et seq., and the Lanham Act, 15 U.S.C. § 1125(a)(1)(B). (Doc. 1).1 On February 5, 2024, Defendant filed its answer, asserting

affirmative defenses, including Plaintiff’s lack of Article III standing to bring suit, and sought attorney’s fees and costs incurred in defending the action. (Doc. 18 at p. 14). On July 29, 2024, Defendant filed a Motion for Summary Judgment on all of Plaintiff’s claims and sought an award for attorney’s fees and costs as the prevailing party pursuant to FDUTPA, Fla. Stat. § 501.2105. (Doc. 31). On February 12, 2025, the Court granted Defendant’s Motion for Summary Judgment, determining that the Plaintiff lacked Article III standing to bring suit. (Doc. 48 at pp. 14-16). The Court concluded that there was no actual controversy between the parties, rendering Plaintiff’s claims moot because Defendant “presented uncontroverted evidence that it ceased compounding and advertising the only

drug mentioned in the Complaint.” (Id. at p. 16); (see id. at pp. 7-8). The next day, on February 13, 2025, the Clerk entered a judgment in favor of Defendant, stating that it was entitled to costs and Plaintiff would take nothing on its claims. (Doc. 49). In the judgment, the Court instructed the parties that any motions seeking an award of attorney’s fees and/or costs must be filed in accordance with Local Rule 7.01. (Id.).

1 Specifically, Plaintiff filed its complaint against Defendant, seeking to enjoin Defendant’s “unlawful business practice” of compounding, marketing, and selling adulterated, misbranded, and non-FDA approved semaglutide drugs containing the body-protecting compound 157 (“BPC-157”) in violation of FDUTPA, Fla. Stat. § 501.201 et seq., and the Florida Drug and Cosmetic Act, Fla. Stat. § 499.001 et seq. (Doc. 1); (see Doc. 48). Plaintiff sought a declaration that Defendant’s business practices violated the Lanham Act, 15 U.S.C. § 1125(a)(1)(B) (Count I), constituted common law unfair competition (Count II), and violated the FDUTPA (Count III), as well as an injunction prohibiting Defendant from committing such violations. (Doc. 1); (see Doc. 48). Following the entry of judgment in its favor, on February 27, 2025, Defendant timely filed the instant Motion for Entitlement to Costs and Attorney’s Fees. (Doc. 52). Defendant seeks entitlement to an award of $250,289.00 in attorney’s fees and $1,807.80 in costs as the purported prevailing party under FDUTPA, Fla. Stat. § 501.2105(1), and the Lanham Act,

15 U.S.C. § 1117(a). (Doc. 52; Doc. 52-1). On March 11, 2025, Plaintiff filed a Notice of Appeal, appealing the Court’s Order granting summary judgment (Doc. 48) and the judgment entered against it (Doc. 49). (Doc. 53). Plaintiff filed its response in opposition to Defendant’s motion on March 13, 2025. (Doc. 55). II. LEGAL STANDARDS As a general matter, when an appeal is pending, the Court has discretion to defer ruling on a motion for attorney’s fees and costs, or it may deny the motion without prejudice and, to the extent necessary, allow leave to file a renewed motion for attorney’s fees and costs after

the appeal has concluded. See Specialized Transp. of Tampa Bay, Inc. v. Nestle Waters N. Am., Inc., No. 8:06-CV-421-T-33EAJ, 2009 WL 1788373, at *1 (M.D. Fla. June 22, 2009); Pub. Risk Mgmt. of Fla. v. Munich Reinsurance Am., Inc., No. 8:18-CV-1449-MSS-AEP, 2021 WL 4393291, at *1 (M.D. Fla. July 9, 2021). Historically, it has been “[t]his Court’s practice . . . to deny motions for attorney’s fees without prejudice when a matter has been appealed.” See Regions Bank v. Legal Outsource PA, No. 2:14-476-FTM-PAM-MRM, 2017 WL 11461033, at *1 (M.D. Fla. Apr. 27, 2017); Pub. Risk Mgmt. of Fla., 2021 WL 4393291, at *1-2 (denying defendant’s motion on entitlement to an attorney of attorneys’ fees and costs without prejudice and allowing the defendant, to the extent necessary, to renew its motion or submit

a supplemental motion following the appeal). “Indeed, such resolution seems most likely to preserve judicial resources, prevent piecemeal litigation of the issue of an award of attorneys’ fees and costs, and promote the interests of efficiency and economy.” Pub. Risk Mgmt. of Fla., 2021 WL 4393291, at *1; see Specialized Transp. of Tampa Bay, Inc., 2009 WL 1788373, at *1 (stating that “[t]his Court

prefers to avoid the piecemeal adjudication of attorney’s fees and costs” because “[i]f th[e] Court were to resolve the attorney’s fees and costs issues while an appeal remains pending, it would likely be asked to repeat the procedure following the appeal); Corey Airport Servs., Inc. v. City of Atlanta, No. 1:04-CV-3243-CAP, 2011 WL 13216938, at *1 (N.D. Ga. Apr. 6, 2011) (noting that “it would be an inefficient use of limited judicial resources to address the plaintiff’s motion for attorney’s fees” while an appeal was pending). III. DISCUSSION Defendant asserts that it is entitled to attorney’s fees and costs as the prevailing party under FDUTPA, Fla. Stat. § 501.2105(1), and the Lanham Act, 15 U.S.C. § 1117(a). (Doc.

52). Defendant estimates their recoverable attorney’s fees in the amount of $250,289.00 and costs in the amount of $1,807.80. (Doc. 52-1). In opposition, Plaintiff argues that Defendant prematurely seeks an award of attorney’s fees and costs under FDUTPA and the Lanham Act in this case, as it recently filed its Notice of Appeal. (Doc. 55 at p. 1). Plaintiff asserts that in light of its pending appeal, which may obviate the need to pay any fees or costs, the Court should hold costs in abeyance until the conclusion of the appeal.

Free access — add to your briefcase to read the full text and ask questions with AI

Novo Nordisk, Inc. v. Wells Pharmacy Network, LLC, (M.D. Fla. 2025).

Novo Nordisk, Inc. v. Wells Pharmacy Network, LLC (Novo Nordisk, Inc. v. Wells Pharmacy Network, LLC) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related